MedPath

A clinical study to study the drug Seenthil Sarkkarai on Neerizhivu

Phase 2
Conditions
Health Condition 1: null- Iya Neerizhivu
Registration Number
CTRI/2018/01/011497
Lead Sponsor
Dr S Neelavathi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Type 2 diabetes mellitus

If yes in any of three

FBS above 110 mg per dl and below and equal 250mg per dl or

PPBS above 160 mg per dl and below and equal 350mg per dl

HbA1c above 6.4 and below 10

Persistent cases of COPD as per the standard key indicators for assessment

FEV1 between above 50 percentage and below 80 percentage of the predicted value

Willing to give blood sample for the investigations

Patients who are mono therapy alone

Exclusion Criteria

Age below 40 and above 70

Type 1 diabetes mellitus

If yes in any of three

FBS below 109 mg per dl and above and equal 251 mg per dl or

PPBS below 159 mg per dl and above and equal 351 mg per dl

HbA1c below 6.3 and above 10.1

FEV1 below 50 percentage and above 80 percentage of the predicted value

Pregnant woman and plan to pregnant six months

Lactating mother

Chronic kidney disease or Renal failure

Corticosteroid therapy

Chronic active hepatitis or cirrhosis or ascites

Multisystem involvement

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The therapeutic efficacy of trial drug Seenthil Sarkkarai on IYA NEERIZHIVUTimepoint: 90 days
Secondary Outcome Measures
NameTimeMethod
Evaluation of Siddha diagnostic parametersTimepoint: 90 days
© Copyright 2025. All Rights Reserved by MedPath